ClinicalTrials.gg
TerminatedNCT05588362ATEGUpdated Oct 19, 2026

Access to EyeGlasses for School-aged Children

An interventional study of Fitz Frames 3-D Printed Glasses in Myopia, Amblyopia and Hyperopia, sponsored by Boston Children's Hospital. Terminated at 1 site in United States. Open to participants aged 5 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by Boston Children's Hospital · Not applicable, Interventional, and Treatment

How we know

Why this study was terminated
Funding was stopped from source before project could start intervention phase of trial
Updated Oct 19, 2026Now TerminatedFirst site in United States+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
5 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 342 studies in Myopia with a site in United States — 27 open to participants now, 44 under way, 3 of them phase 3. Myopia · United States.

Enrollment
196th of 294
50 · median 68
Started
2024
with 19 others
No phase
243 of 342
16 open now
Registered
256th of 342
by date

Among the 342 studies in Myopia with a site in United States, this one is the 196th largest by enrollment of the 294 interventional ones that give a count, is one of 20 that started in 2024, is one of 243 with no phase, and was the 256th registered.

Myopia

1,166 studies on the registry are indexed under Myopia; 228 are open to participants now.

Browse Myopia studies →

Open to participants now

27 of the 342 studies in Myopia with a site in United States are open now. Recruiting first, the newest first:

22 more — sign in →

All 27 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 124 Myopia studies recruiting now, 20 (16%) set no upper age limit and 103 (83%) stop at 75 or younger; 85 take children under 18; 53 take healthy volunteers.

This study: 5 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 342 studies in Myopia with a site in United States, or all of them as a file.
02

Study summary

Uncorrected refractive error is a leading cause of visual impairment in children and can impact vision, quality of life, and academic performance. Despite Boston Children's Hospital serving patients from a wide range of socioeconomic backgrounds, there are health disparities in access to eyeglasses as a consequence of patients' health insurance. The investigators will examine whether the use of an in-clinic app for 3-D printed glasses reduces disparities in access to eyeglasses for our patients on Medicaid. The intervention will address social determinants of health and improve pediatric health outcomes namely, how and when children having publicly funded health insurance receive eyeglasses. The short-term objectives are (1) to compare the time to receive glasses between publicly funded MassHealth eyeglasses and an in-clinic order of 3D printed glasses (2) to evaluate compliance with glasses wear in these two groups, and (3) to evaluate visual function and quality-of-life outcomes in these two groups. This prospective randomized control study will evaluate barriers to accessing eyeglasses in school-aged children. The investigators will recruit children enrolled in MassHealth and randomize them into two cohorts: (1) the control group will receive MassHealth glasses as per standard of care, through an optical shop of their choosing, or (2) the intervention group will use an app for immediately ordering glasses (paid for by the study) in clinic following their appointment. The investigators will evaluate the time needed to receive eyeglasses, compliance with glasses wear, quality of life, and visual outcomes between the cohorts at one-, three-, and six-month intervals. Through this project, the investigators will not only evaluate, quantify, and bring awareness to disparities in our patient population, but will also look toward finding a solution through the use of a novel application that addresses many of the barriers faced by patients insured through Medicaid.

03

Conditions studied

  • Myopia
  • Amblyopia
  • Hyperopia
  • Refractive Errors
04

Who can participate

Ages eligible
5 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Masshealth insurance
  • first-time glasses wearers
  • receive a diagnosis of refractive amblyopia, myopia, hyperopia and/or astigmatism requiring spectacle correction for optimal vision at distance and near.
  • Glasses must be recommended for full time wear by the attending optometrist or ophthalmologist

Exclusion criteria

Exclusion Criteria:

  • strabismus
  • developmental or learning delay
  • other ocular pathology
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    Fitz Frames 3-D Printed Glasses

    The intervention group will order glasses directly in the office following their exam and consent using an iPad with the help of the research assistant. The iPad will be e-connected to a 3D printed glasses manufacturer (Fitz Frames) through their application, allowing the child (with assistance from the doctor or research assistant) to take various measurements in real time. Sixteen different measurements will be taken including interpupillary distance, face length, face width, and temple measures. The child will be able to choose frame style and order it directly from the manufacturer immediately following the exam. Glasses will be shipped directly to the patient's home (shipping address will be input to the app by the family).

    Other: Fitz Frames 3-D Printed Glasses

  • No intervention
    Traditional Glasses Procurement Group

    (1) The control group will receive standard of care in which a prescription for glasses will be dispensed as a paper copy prescribed by the examiner before randomization. The research assistant will use a script (attached) that instructs families how to procure glasses traditionally through Masshealth. The participant/family will be instructed to bring the paper prescription to an optical shop that carries MassHealth frames. A printout of local optical shops that carry MassHealth frames will be provided to the patient.

Interventions

  • OtherFitz Frames 3-D Printed Glasses

    The intervention group will order glasses directly in the office following their exam and consent using an iPad with the help of the research assistant. The iPad will be e-connected to a 3D printed glasses manufacturer (Fitz Frames) through their application, allowing the child (with assistance from the doctor or research assistant) to take various measurements in real time. Sixteen different measurements will be taken including interpupillary distance, face length, face width, and temple measures. The child will be able to choose frame style and order it directly from the manufacturer immediately following the exam. Glasses will be shipped directly to the patient's home (shipping address will be input to the app by the family).

06

What researchers measure

Primary outcomes

  1. Compliance

    Glasses compliance will be assessed with self-reported calendar

    Time frame: Six months

  2. Quality of Life Questionnaire

    Quality of life measures using the PedEyeQ

    Time frame: Baseline, will be collected at enrollment visit

  3. Distance visual acuity

    Linear Snellen optotypes (age \>6) or HOTV matching with crowding bars (age \<6)

    Time frame: Baseline, will be collected at enrollment visit

  4. Distance visual acuity

    Linear Snellen optotypes (age \>6) or HOTV matching with crowding bars (age \<6)

    Time frame: 0-3 Months, will be collected at 3 month visit

  5. Distance visual acuity

    Linear Snellen optotypes (age \>6) or HOTV matching with crowding bars (age \<6)

    Time frame: 3-6 Months, will be collected at 6 month visit

  6. Stereoacuity

    Stereo Fly test

    Time frame: Baseline, will be collected at enrollment visit

  7. Stereoacuity

    Stereo Fly test

    Time frame: 0-3 Months, will be collected at 3 month visit

  8. Stereoacuity

    Stereo Fly test

    Time frame: 3-6 Months, will be collected at 6 month visit

  9. Ocular alignment

    Alternative prism cover test at distance and at near

    Time frame: Baseline, will be collected at enrollment visit

  10. Ocular alignment

    Alternative prism cover test at distance and at near

    Time frame: 0-3 Months, will be collected at 3 month visit

  11. Ocular alignment

    Alternative prism cover test at distance and at near

    Time frame: 3-6 Months, will be collected at 6 month visit

  12. Near point of convergence

    Near point of convergence (break point and recovery) will be measured using an accommodative target

    Time frame: Baseline, will be collected at enrollment visit

  13. Near point of convergence

    Near point of convergence (break point and recovery) will be measured using an accommodative target

    Time frame: 0-3 Months, will be collected at 3 month visit

  14. Near point of convergence

    Near point of convergence (break point and recovery) will be measured using an accommodative target

    Time frame: 3-6 Months, will be collected at 6 month visit

  15. Near visual acuity

    Near visual acuity will be measured at 40 cm using the Rosenbaum card

    Time frame: Baseline, will be collected at enrollment visit

  16. Near visual acuity

    Near visual acuity will be measured at 40 cm using the Rosenbaum card

    Time frame: 0-3 Months, will be collected at 3 month visit

  17. Near visual acuity

    Near visual acuity will be measured at 40 cm using the Rosenbaum card

    Time frame: 3-6 Months, will be collected at 6 month visit

  18. Quality of Life Questionnaire- PedEyeQ

    Quality of life measures using the PedEyeQ

    Time frame: 0-3 Months, will be collected at 3 month visit

  19. Quality of Life Questionnaire- PedEyeQ

    Quality of life measures using the PedEyeQ

    Time frame: 3-6 Months, will be collected at 6 month visit

07

Study locations

1 site
  • Boston Children's Hospital
    Boston, Massachusetts 02118, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Apr 2024 to primary completion in May 2025, 13 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 19, 2026: start Feb 2023 → Apr 2024, primary completion Nov 2023 → May 2025 and completion Dec 2023 → May 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 3, 2022
First posted
Oct 20, 2022
StartActual
Apr 1, 2024was Feb 2023
Primary completionActual
May 30, 2025was Nov 2023
CompletionActual
May 30, 2025was Dec 2023
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Terminated Funding was stopped from source before project could start intervention phase of trial
changed Oct 19, 2026
Sites
1 site added — first site in United States
Show site
  • Boston Children's Hospital · Boston, United States
Oct 19, 2026
Start date
Feb 1, 2023→Apr 1, 2024 (actual)
Oct 19, 2026
Primary completion
Nov 30, 2023→May 30, 2025 (actual)
Oct 19, 2026
Study completion
Dec 30, 2023→May 30, 2025 (actual)
Oct 19, 2026
Enrollment
72 (estimated)→50 (actual)
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    Status unknown→Terminated
    Why stopped Funding was stopped from source before project could start intervention phase of trial
    1 site added — first site in United States
    Show site
    • Boston Children's Hospital · Boston, United States
    Start date Feb 1, 2023→Apr 1, 2024 (now actual)
    Primary completion Nov 30, 2023→May 30, 2025 (now actual)
    Study completion Dec 30, 2023→May 30, 2025 (now actual)
    Enrollment 72 (estimated)→50 (actual)
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05588362
Collaborators
Fitz Frames, Inc.
Responsible party
Emily Wiecek (Optometrist, Boston Children's Hospital) — Principal investigator
First posted
Oct 20, 2022
Start date
Apr 1, 2024
Primary completion
May 30, 2025
Completion
May 30, 2025
Last update
Oct 19, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion